Table 3 Multivariate analysis of total Cat X concentration and other potential factors for overall survival of 178 patients in stages I-III
From: Prognostic and predictive value of cathepsin X in serum from colorectal cancer patients
HR | 95% CI | p-value | |
|---|---|---|---|
Gender | |||
Female | 0.62 | 0.37-1.06 | |
0.08 | |||
Male | 1.0 | ||
Age (per 10 years) | 1.58 | 1.24-2.02 | 0.0003 |
Stage | |||
I | 1.0 | ||
II | 1.23 | 0.58-2.62 | 0.01 |
III | 2.74 | 1.27-5.92 | |
Localisation | |||
Right-sided colon cancer | 1.00 | ||
Left-sided colon cancer | 1.18 | 0.61-2.28 | 0.79 |
Rectal Cancer | 0.99 | 0.48-2.05 | |
CEA (≥ 5 ng/ml vs. < 5 ng/ml) | |||
No adjuvant chemotherapy | 1.99 | 1.14-3.50 | 0.026 |
Adjuvant chemotherapy | 0.42 | 0.13-1.39 | 0.60 |
Cat X (2-fold difference in HR) | |||
No adjuvant chemotherapy | 3.13 | 1.37-7.18 | 0.003 |
Adjuvant chemotherapy | 0.51 | 0.20-1.33 | 0.88 |